Advertisement


Roisin M. Connolly, MD, on Breast Cancer Treatment Advances in 2018: Expert Perspective

2018 San Antonio Breast Cancer Symposium

Advertisement

Roisin M. Connolly, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discusses clinical trials during the past year on studies on CDK and PI3K inhibitors in estrogen receptor–positive breast cancer and immune checkpoint agents in triple-negative breast cancer.



Related Videos

Breast Cancer

Andrew D. Seidman, MD, and Miguel Martín, MD, PhD, on Triple-Negative Breast Cancer: Results From the CIBOMA/GEICAM Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Miguel Martín, MD, PhD, of the Instituto de Investigacion Sanitaria Gregorio Marañón, discuss...

Breast Cancer
Genomics/Genetics

Dejan Juric, MD, on Advanced Breast Cancer: Results From the SOLAR-1 Trial

Dejan Juric, MD, of Massachusetts General Hospital, discusses phase III study findings on liquid biopsy–based assessment of PIK3CA mutational status and the combination of...

Breast Cancer

Eva M. Ciruelos, MD, PhD, on HER2-Positive Breast Cancer: Results From the PATRICIA Trial

Eva M. Ciruelos, MD, PhD, of the University Hospital 12 de Octubre and the SOLTI Group, discusses study findings on palbociclib and trastuzumab in postmenopausal patients with HER2...

Breast Cancer

Kathryn J. Ruddy, MD, MPH, on Breast Cancer and Quality of Life: Expert Perspective

Kathryn J. Ruddy, MD, MPH, of the Mayo Clinic, summarizes a special spotlight session that included discussion of interventions to improve quality of life and the importance of lif...

Breast Cancer

Andrew D. Seidman, MD, and Charles E. Geyer, MD, on HER2-Positive Breast Cancer: Results From the KATHERINE Trial

Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Charles E. Geyer, MD, of Virginia Commonwealth University, discuss phase III study findings o...

Advertisement

Advertisement



Advertisement